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Bacteroides fragilis is the leading cause of anaerobic bacteremia and sepsis 1 . Enterotoxigenic strains that produce B. fragilis toxin (BFT, fragilysin) contribute to colitis 2 and intestinal malignancy 3 , yet are also isolated in bloodstream infection 4, 5 . It is not known whether these strains harbor unique genetic determinants that confer virulence in extra-intestinal disease. We demonstrate that BFT contributes to sepsis in mice, and we identify a B. fragilis protease called fragipain (Fpn) that is required for the endogenous activation of BFT through the removal of its auto-inhibitory prodomain. Structural analysis of Fpn reveals a His-Cys catalytic dyad that is characteristic of C11-family cysteine proteases that are conserved in multiple pathogenic Bacteroides spp. and Clostridium spp. Fpn-deficient, enterotoxigenic B. fragilis has an attenuated ability to induce sepsis in mice; however, Fpn is dispensable in B. fragilis colitis, wherein host proteases mediate BFT activation. Our findings define a role for B. fragilis enterotoxin and its activating protease in the pathogenesis of bloodstream infection, which indicates a greater complexity of cellular targeting and activity of BFT than previously recognized. The expression of fpn by both toxigenic and nontoxigenic strains suggests that this protease may contribute to anaerobic sepsis in ways that extend beyond its role in toxin activation. It could thus potentially serve as a target for disease modification.
Anaerobic bacteremia caused by B. fragilis organisms afflicts individuals with acute intestinal injury and underlying disease, including malignancy, an immunocompromised state, inflammatory bowel disease, congestive heart failure, and diabetes 6, 7 . The disruption of intestinal barrier function in people with these predisposing conditions precipitates extra-intestinal infection, including bacteremia and sepsis 8, 9 , and results in a ~3-5-fold greater mortality risk and an increased length of hospital stay, as compared to clinically matched controls without infection, as well as the need for more aggressive therapeutic and surgical interventions, especially in the settings of diverticulitis and overt colonic injuries 6,10-12 . B. fragilis is the leading cause of anaerobic sepsis 6, 7, 13 . Although experimental immunization that targets B. fragilis capsular polysaccharide protects against bacteremia associated with intra-abdominal sepsis 14 , the virulence factors that contribute to severe infection of the bloodstream are not well defined. Rising rates of antimicrobial resistance prompt the need for a better understanding of the mechanisms that underlie B. fragilis sepsis 13, 15, 16 .
Nearly 20% of B. fragilis bloodstream isolates harbor a 6-kb pathogenicity island that encodes B. fragilis enterotoxin (BFT, fragilysin), which is absent from nontoxigenic B. fragilis (NTBF) 4, 5, 17 . Toxin-producing isolates are enriched in the bloodstream relative to other sites of extra-intestinal infection 4 , which suggests that these strains exhibit enhanced survival and virulence in the bloodstream. BFT is a zinc-dependent metalloprotease with a structural homology to metallopeptidases of the eukaryotic a disintegrin and metalloprotease (ADAM) family 2,3,18-21 . BFT is the only recognized virulence factor in enterotoxigenic B. fragilis (ETBF), and it promotes colonic injury and inflammation through E-cadherin cleavage 3, 20, 22 . The proteolytic cleavage of cadherins by the zinc-dependent metalloprotease ADAM10 contributes to the pathogenesis of Staphylococcus aureus infection through tissue-barrier disruption [23] [24] [25] . Given the similarity of BFT to ADAM metalloproteases 21 , we examined whether BFT contributes to the pathogenesis of lethal sepsis. Mice were infected intravenously with 1 × 10 9 colony-forming units (CFU) of either wildtype (WT) ETBF, an isogenic bft mutant (∆bft), or the ∆bft strain complemented with bft (cbft). Mice infected with WT ETBF or cbft experienced lethal sepsis, whereas mice infected with ∆bft survived (Fig. 1a) . BFT was sufficient for lethality: mice succumbed to intoxication with purified BFT (Fig. 1b) , but not to infection with a catalytically inactive mutant (iBFT) 26 .
BFT is produced as a 45-kDa zymogen with an N-terminal prodomain that facilitates folding and enzyme latency 21 . During toxin maturation, an unidentified protease mediates prodomain removal at the position C-terminal to R211 (ref. 27) . To define the factors that are required for active BFT production, we examined supernatants from transposon mutant ETBF clones for an inability to disrupt intracellular junctions in colonic epithelial HT-29 cells derived from a colorectal carcinoma ( Supplementary Fig. 1a ) 20 . Of 84 defective mutants, secondary screening identified two that lacked the cleaved 20-kDa active BFT moiety (BFT*) ( Fig. 2a) . l e t t e r s 5 6 4 VOLUME 22 | NUMBER 5 | MAY 2016 nature medicine Transposon-insertion mapping revealed two sites upstream of a gene annotated in B. fragilis NTBF strain NCTC 9343 as a peptidase similar to the Bacteroides thetaiotaomicron clostripain-related protein (Fig. 2b) . RT-qPCR confirmed a reduction in peptidase expression ( Supplementary Fig. 1b) . The clostripain-related peptidase is a 393 amino acid protein with a predicted molecular weight of 44,160 Da ( Supplementary Fig. 2 ; GenBank KT867680). Sequence alignment of this peptidase with homologous proteins in NTBF, in other Bacteroides species, and with Clostridium histolyticum clostripain revealed conservation of the His-Cys catalytic dyad 28 ( Fig. 2c and Supplementary Fig. 2a ; asterisks) in the context of a -His-Gly-(Xaa) n -Ala-Cys-sequence motif ( Fig. 2c , blue boxes), which is common to clan CD cysteine proteases 29 . It also revealed an N-terminal lipobox motif that is conserved in B. fragilis ( Supplementary Fig. 2a , orange box). B. fragilis 638R is predicted to encode a clostripain-like polypeptide that lacks 15 N-terminal residues. Analysis of the 638R genome, as compared to that of the nontoxigenic B. fragilis strain NCTC 9343, revealed an insertional mutation ( Supplementary Fig. 2b) , which resulted in a loss of protein production ( Supplementary Fig. 2c) . The peptidase appears as two immunoreactive species, which is consistent with the clostripain heavy-and light-chain heterodimer that is formed upon autocatalytic cleavage 30 . C. histolyticum clostripain is a C11 cysteine protease that exhibits specificity for an Arg-Xaa peptidyl bond 29 . We hypothesized that the clostripain-like protein activates BFT, and we designated it fragipain (Fpn).
To evaluate the necessity of Fpn for BFT activation, an fpn deletion was generated in ETBF (∆fpn) and complemented with the genomic insertion of fpn (cfpn). These strains displayed growth properties in vitro that are indistinguishable from those of the parental strain ( Supplementary Fig. 3a ). Fpn-transcript and Fpn-protein production were verified through RT-qPCR ( Supplementary Fig. 3b ) and immunoblot analysis ( Fig. 2d) . Fpn deletion resulted in the absence of active BFT in culture supernatants ( Fig. 2e ) and the loss of E-cadherin cleavage in HT-29 cells ( Fig. 2f) , both of which were restored by complementation. npg When recombinant proteins were used, Fpn was sufficient for native BFT cleavage. Edman degradation of the BFT reaction product demonstrated cleavage at R211, as was observed in culture supernatants ( Fig. 2g) 27 . The mutation of BFT R211 (BFT R211A ) resulted in the generation of a species with a molecular weight higher than that of BFT*, acting through R162 cleavage on a surface-exposed loop 21 . Fpn variants harboring mutations of predicted active-site residues (Fpn H135A , Fpn C180A , and Fpn H135AC180A ) were unable to cleave BFT. Fpn-activated BFT facilitated E-cadherin cleavage in HT-29 cells (Fig. 2g, bottom) ; the amount of cleavage to the active toxin moiety was reduced in BFT R211A upon Fpn exposure.
Recombinant Fpn was crystallized for X-ray diffraction and structure determination. The structure was solved through molecular replacement, using a homology model based on a Parabacteroides merdae putative protease (37% sequence identity; Protein Data Bank (PDB) code: 3UWS) and refined to a resolution of 2.48 Å ( Fig. 3 and Supplementary Table 1 ; PDB code: 5DYN). Fpn is composed of 11 α-helices around a β-scaffold that consists of nine β-strands (β1-β5 and β9-β12), and five additional β-strands (scaffold β6-β8 and hairpin β13-β14) are present at the surface (Fig. 3a,b) . Fpn is cleaved at the Arg-Trp peptidyl bond ( Fig. 3a, green) in the loop that connects β-strands six and seven. The cleaved loop of Fpn projects into the catalytic site of an adjacent Fpn molecule ( Fig. 3c) , which is demonstrated in a composite omit map of the electron density of the active site ( Fig. 3d) that reveals a cysteine-protease cleavage product bound in trans. Residues H135 and C180 (Fig. 3a, red) , which form the catalytic dyad, are positioned 2.9 Å and 3.1 Å from the npg main-chain oxygen of substrate residue R147 (Fig. 3e) . The structure suggests autocatalytic cleavage of Fpn and a classical cysteine-protease mechanism, whereby H135 deprotonates C180 and thus promotes C180 attack on the substrate carbonyl. S44 (Fig. 3a, purple) has a close interaction with H135 ( Fig. 3e) , which may position the imidazole ring of H135 for C180 deprotonation. The structure reveals water contact with H135 ( Fig. 3c ) and the oxygen of the main-chain arginine. As in papain, this water molecule may deacylate the acyl-enzyme intermediate, and release the cleaved carboxy peptide [31] [32] [33] . In a manner consistent with this mechanism of action, Fpn exhibits optimal activity at neutral pH (Supplementary Fig. 3c) .
To examine the role of Fpn in BFT-mediated disease, antibioticpretreated mice received 1 × 10 9 CFU of WT, ∆bft, ∆fpn, or cfpn B. fragilis via oral gavage and were examined for colitis. Although fecal CFU and weight gain were similar across groups ( Supplementary  Fig. 4a,b) , mice infected with WT, ∆fpn, and cfpn exhibited crypt hypertrophy and epithelial shedding ( Fig. 4a) and an increase in the colon weight-to-length ratio relative to that observed in mice infected with ∆bft ( Fig. 4b) . ∆bft-infected mice did not demonstrate signs of colitis. Consistent with the lack of a requirement for Fpn in BFT-mediated intestinal injury, colonic mucus harvested from specific-pathogen-free (SPF) and germ-free (GF) mice mediated BFT cleavage ( Fig. 4c, BFT*) . In contrast, Fpn was required for lethal sepsis progression. B. fragilis ∆fpn was avirulent upon intravenous infection (Fig. 4d) , which mirrors the phenotype observed upon BFT deletion ( Fig. 1a) and demonstrates a tissue-specific requirement for Fpn in toxin activation.
Whereas the colonic epithelial barrier is recognized as an important target of BFT 20 , the role of BFT and Fpn in sepsis suggested a broader cellular tropism. Loss of endothelial-barrier integrity is a primary pathophysiologic alteration in sepsis 34 . We therefore examined whether the vascular endothelium is directly injured by BFT. In contrast to treatment with media or inactive toxin, the treatment of human pulmonary artery endothelial cells (HPAECs) with BFT resulted in a loss of junctional VE-cadherin ( Fig. 4e) , which we confirmed through the generation of a C-terminal cadherin fragment consistent with metalloprotease-dependent cleavage (Supplementary Fig. 5 ) 23 .
These studies define a role for BFT in sepsis in mice and reveal that a novel B. fragilis protease is required for extra-intestinal toxin activation to confer virulence. Although the molecular pathogenesis of life-threatening systemic disease associated with staphylococcal enterotoxins and Shiga toxins is well characterized 35, 36 , little insight is available into the systemic complications from enterotoxins that are produced by anaerobic intestinal commensals. The structural similarity of BFT to ADAM metalloproteinases 21 and our demonstration that BFT targets VE-cadherin indicate that activated BFT has a functional role in disrupting barrier integrity, akin to the role of ADAM10 in S. aureus sepsis 23, 24 . These studies highlight the role of ADAM-family metalloproteases in sepsis-associated endovascular injury, whether caused directly by BFT or after the catalytic activation of host ADAM10 induced by S. aureus α-toxin [23] [24] [25] 37 . Given that expression-enhancing human ADAM10 polymorphisms are associated with increased susceptibility to severe sepsis 38 , differential levels of active BFT expression may modulate the severity of B. fragilis-induced sepsis. The identification of a role for BFT in sepsis therefore provides an opportunity to understand the molecular pathogenesis of anaerobic infection and to examine clinical outcomes in individuals infected with toxin-producing strains, including in the context of polymicrobial infections. B. fragilis remains the leading cause of anaerobic sepsis 6, 11 , and so our observations are anticipated to stimulate investigation into novel preventive and therapeutic interventions that would be applicable to the ever-growing population of people who are receiving advanced medical care. Of keen interest is the potential development of targeted probiotic therapy to eradicate toxigenic B. fragilis in individuals who are at high risk for sepsis.
Further studies are needed to develop a mechanistic understanding of BFT and Fpn bloodstream activation, to identify cellular targets of toxin action, and to examine whether fpn expression by nontoxigenic B. fragilis promotes disease. To our knowledge, Fpn is the first C11 peptidase to be implicated in sepsis. C11-family cysteine proteases are widely present in pathogenic Bacteroides spp. and Clostridium spp. (http://merops.sanger.ac.uk/cgi-bin/famsum?family=c11) 39 , and they are collectively responsible for more than 50% of anaerobic bacteremia 1, 10 . The unique relevance of Fpn in BFT activation in the bloodstream may therefore also prompt a broader investigation of C11 proteases in extra-intestinal infection.
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Accession codes. GenBank: Fpn sequence data have been deposited with accession code KT867680; Protein Data Bank: Fpn structural data have been deposited with accession code 5DYN. 
ONLINE METHOdS
Bacterial and eukaryotic cell culture. The ETBF strains used in these studies were ATCC 43858 and ATCC 43859. The NTBF strains used were NCTC 9343 (ATCC 25285) and 638R (TM4000). B. fragilis strains were propagated anaerobically at 37 °C in Brain Heart Infusion (BHI) medium supplemented with 0.0005% hemin and 0.5 µg/ml vitamin K1 (BHIS). Media was supplemented with 200 mg/L gentamicin and 5 mg/L erythromycin or 5 mg/L clindamycin for selection of strains harboring drug-resistance loci. E. coli S17 was used for the propagation and conjugation of plasmids that were introduced into B. fragilis, and E. coli Origami-2 (Novagen) was used for protein purification. E. coli were maintained in LB supplemented with 50 mg/L kanamycin for strains containing the pET28b vector or 100 mg/L ampicillin for all other vectors. For conjugations, equal volumes of late log phase E. coli and B. fragilis cultures were washed once with BHI, mixed, plated as a puddle on BHIS or Luria-Bertani (LB) agar, and incubated aerobically at 37 °C overnight, as modified from a previously published protocol 40 . Bacteria were then resuspended in BHI, plated onto BHIS agar containing gentamicin and erythromycin or clindamycin, and grown anaerobically. HT-29 cells were obtained from the American Type Culture Collection (ATCC) and propagated in DMEM supplemented with 10% fetal bovine serum and 2 mM l-glutamine. HT-29 cells were authenticated by the ATCC through short-tandem-repeat profiling and cell morphology, and confirmed to be contaminant-free before distribution. Primary human pulmonary artery endothelial cells (HPAECs; Lonza) were cultured in Endothelial Basal Medium-2 (EBM-2) BulletKit media (Lonza).
Animal modeling.
All animal studies were conducted in accord with all ethical regulations under protocols approved by the University of Chicago Animal Care and Use Committee and Institutional Biosafety Committee. Female C57BL/6 mice were bred in-house from mice originally purchased from Jackson Laboratory or purchased from Jackson Laboratory and maintained under specific-pathogen-free conditions for use in experimentation at 4 weeks of age. Sample-size estimates for animal experiments were based on prior animal-modeling studies used in the laboratory for the investigation of lethal infectious disease and colitis. At the time of weaning, animals were randomly distributed for use in experimentation. There was no investigator blinding in animal experimentation, and no animals were excluded from analysis.
Intravenous infection. Overnight cultures of B. fragilis were subcultured at a 1:100 ratio into fresh BHIS and grown for 14-15 h. Cells from 25-ml culture were sedimented and resuspended in 15 mL of phosphate-buffered saline (PBS). These suspensions were adjusted through the addition of PBS until a 1:5 dilution yielded OD 600 = 0.55. Bacteria from 9 ml of suspensions were sedimented, resuspended in a volume of PBS empirically determined to yield a cell density of 1 × 10 10 CFU per ml. Prior to the retro-orbital delivery of 0.1 ml of the bacterial inoculum, mice were anesthetized with ketamine (100 mg/kg) delivered via an intraperitoneal route. The number of CFU in each inoculum was confirmed by serial dilution plating on BHIS agar. Mice were euthanized at time points indicated in the results or when moribund, in accord with criteria established in the animal-use protocol.
Colitis modeling. Mice were pre-treated with 100 mg/L of clindamycin in drinking water for 1 week before and throughout the course of infection. To prepare inocula, overnight cultures of B. fragilis were subcultured at a 1:50 ratio into fresh BHIS and grown until they reached OD 600 ≈ 0.5. Bacteria from 50-ml culture were sedimented and processed, as for intravenous infection. After the final centrifugation, bacteria were resuspended in 1.8 ml of 0.1-N sodium bicarbonate to yield a concentration of 10 10 CFU per ml. Infection was accomplished by oral gavage of 0.1 ml of each inoculum. The number of CFU in each inoculum was confirmed by serial dilution plating on BHIS agar. To analyze fecal CFU after oral inoculation, fecal pellets were collected from individual mice, weighed, and vortexed in 1 ml PBS to achieve complete resuspension. Serial tenfold dilutions were plated on BHIS agar containing gentamicin and clindamycin to determine CFU per g of feces. For histopathologic analysis of infected colonic tissue, mice were euthanized 1 week after infection, and colons were dissected from the mice and immediately injected with 10% formalin. After the removal of fecal pellets, the colon was opened longitudinally and Swiss-rolled around a toothpick, starting from the distal colon with the mucosal surface facing outward. Tissue rolls were fixed in 10% formalin overnight. Paraffin embedding, tissue sectioning, and H&E staining were performed by Nationwide Histology. Imaging was performed at the University of Chicago Integrated Light Microscopy Facility. Digital image files were created with a 3D Histech Pannoramic Scan whole-slide scanner (Perkin Elmer, Waltham, MA) with a Stingray F146C color camera (Allied Vision Technologies, Stadtroda, Germany). Individual images were created with the 3D Histech Pannoramic Viewer software (Perkin Elmer, Waltham, MA).
Generation of polyclonal antisera. Purified cleaved BFT and Fpn were administered to New Zealand White rabbits. A total of 2.25 mg of protein was administered in three injections given in 3-week intervals. Complete Freund's adjuvant was used for the initial immunization and incomplete Freund's adjuvant for the remaining boosts. Serum was collected starting 3 weeks after the last boost, and reactivity to the proteins of interest was determined by immunoblot analysis of purified protein.
Preparation of intestinal mucus. Germ-free mice and SPF mice were fasted for 8 h before dissection. The colon was harvested from each mouse and opened longitudinally with removal of residual fecal matter to permit the preparation of intestinal mucus, as previously described 41 .
Bacterial studies. Transposon-mutagenesis screen. To generate transposon mutants, the pSAM-Bt vector 42 was introduced to ATCC 43858 via conjugation with a donor E. coli S17 strain. Clones with transposon insertions were selected on BHIS agar containing gentamicin and erythromycin, used to inoculate BHIS liquid media containing antibiotics, and grown overnight in deep 96-well plates. 1:100 dilutions of culture supernatants in serum-free DMEM were used to treat semi-confluent HT-29 cell monolayers for 3 h. Cells were fixed in 10% formalin, stained with 0.05% Crystal Violet for 5 min, washed with water, and screened visually. Screening PCR of transposon mutants was performed using the GoTaq system (Promega). Cloning and inverse PCR was performed using the Phusion system (ThermoFisher). For inverse PCR, genomic DNA was prepared using the Wizard Genomic DNA Extraction kit (Promega), digested with BstNI (NEB), and then treated with T4 ligase (NEB). PCR was performed on this DNA using primers that annealed in the transposon. PCR products were gel extracted and sequenced. Supplementary Table 2 describes all primers used for cloning and PCR-based analysis.
Reverse transcription-quantitative PCR. Bacteria were harvested at the indicated times with RNA Protect (Qiagen). RNA was extracted using the RNeasy kit (Qiagen) and reverse transcribed with random priming, using the iScript cDNA Synthesis kit (Bio-Rad). qPCR was performed on cDNA, RNA, and water controls using the SYBR Green kit (Bio-Rad) and the Bio-Rad CFX96 realtime system with a C1000 thermal cycler. Standard curves for PCR efficiency determination were derived from tenfold serial dilutions of pooled cDNA. Expression levels were compared by normalizing fpn transcript to the amount of 16S transcript present in each sample.
Bacterial plasmids and generation of bacterial strains. To generate isogenic ∆bft and ∆fpn strains, 1-kb genomic regions flanking the target gene were cloned from ETBF ATCC 43859, fused together, and ligated into the pKNOCK suicide vector 43 using KpnI and BamHI sites. The vector was conjugated into ETBF ATCC 43859 that were then plated on BHIS agar containing gentamicin and clindamycin. Serial passaging of the resulting clones was performed, and clones were screened for loss of pKNOCK by clindamycin sensitivity and PCR with primers to document the deletion of the targeted locus. Loss of protein expression was confirmed by performing western blot analysis.
To restore bft and fpn gene expression in isogenic deletion mutants, we generated the pAH1 vector that enables stable insertion into the genome. We identified a targetable insertion site in an intergenic region present in the genomes of multiple published strains of B. fragilis. This site is downstream of genes on the 5′ and 3′ ends to prevent the disruption of native loci. The selected intergenic region was cloned into the suicide vector pKNOCK to generate the vector pAH1. To generate cbft and cfpn B. fragilis strains, bft or fpn loci with the corresponding upstream regions were cloned and fused downstream of the rpoD promoter, then ligated into pAH1. These constructs were introduced to ∆bft or ∆fpn strains via conjugation, and integration of the construct into the correct site and protein expression were confirmed by PCR and western blot, respectively. To generate clindamycin-resistant ∆bft and ∆fpn strains for mouse infection, pAH1 was introduced via conjugation.
npg Crystallographic data collection and data processing. Diffraction from the majority of crystals was poor. The best crystal diffracted to d min = 2.48 Å; a single data set (180 images) was collected from this crystal at a temperature of 100 K using a 1-degree oscillation range on beamline 21-ID-F (LS-CAT, Advanced Photon Source, Argonne, Illinois). Images were collected on a MAR Mosaic 225 detector. Diffraction images were processed using the xia2 data reduction suite 44 and applying the -3da XDS 45 and Aimless 46 options, which were accessed through the SBGrid consortium 47 . Geometric refinement and examination of the scaled amplitudes revealed that Fpn crystals belong to the orthorhombic space group P2 1 2 1 2, with cell dimensions a = 124.32 Å, b = 48.90 Å, c = 60.88 Å (α = β = γ = 90°) (Supplementary Table 1) . The structure was solved by molecular replacement in Phenix 48 , using a model of Fpn that was based on the structure of a hypothetical protein from P. merdae (PDB code: 3UWS). For purposes of the molecular-replacement search, the number of Fpn molecules in the asymmetric unit was estimated using the Matthews Probability Calculator web server (http://www.ruppweb.org/mattprob/). The Fpn search model was generated using the Expasy Swiss-model Workspace server 49 . Molecular replacement revealed one Fpn molecule in the crystallographic asymmetric unit. The initial structural model was manually examined and corrected; ions, and water molecules were added, and refinement of the structure was conducted iteratively using Coot 50 and phenix.refine 48 . The final structural model was refined to an R work of 17.5% and R free of 22.3%. Crystallographic data and refined model statistics are presented in Supplementary Table 1 .
Statistical analysis. Statistical analysis was performed using GraphPad Prism software. Pairwise comparisons were performed using the Student's unpaired two-sided t test, or the Mantel-Cox log-rank test for comparison of survival after Kaplan-Meier estimation. Comparison of variances was performed in GraphPad using the F test, providing documentation of similar variance between groups.
